- WPD Pharmaceuticals (WBIO) collaborator, Wake Forest University, has acquired a European patent for drugs which may target and eliminate cancers.
- WPD now has exclusive patents for these drugs in Europe and the U.S., and will continue their current pre-clinical drug studies.
- The company has also retained Caelum Finance Ltd. and Strike Communications Inc. as corporate consultants.
- WPD’s share price is up 18.27 per cent, with shares trading at $1.23 apiece.
Pharmaceutical company WPD’s (WBIO) collaborator, Wake Forest University, has successfully acquired 2 European patents for drugs which may target and eliminate various cancers.
Patent EP No. 2970492 is for Antibodies against human and canine IL-12RA2. Patent EP No. 3068797 is for EphA3 and Multi-Valent Targeting of Tumours.
Through their ongoing collaborations with Wake Forest University, WPD now has exclusive patents for these drugs in Europe and the U.S.
According to Mariusz Olejniczak, CEO of WPD, “Both IL-13 and EphA3 were shown to be important factors in eliminating tumor cells related to various forms of cancer, and our development of these proteins is incredibly important. […] Our focus is to advance our current pre-clinical studies”.
WPD has also engaged 2 companies to act in an advisory capacity.
Caelum Finance Ltd. will provide WPD with corporate advice on company strategy and business development. Strike Communications Inc. will assist with corporate communications and investor relationship advice.
WPD’s share price is up 18.27 per cent, with shares trading at $1.23 apiece.
